Diagnostics & Research · Healthcare
Board Member
2025-01-01–present
Analyst
Investor
Analyst
Ladenburg Thalmann & Company
Board Member
Aspira Women's Health Inc. (AWHL)Equibles does not estimate personal net worth.
Jeffrey Cohen is recorded as Analyst at Investor, Analyst at Ladenburg Thalmann & Company and Board Member at Aspira Women's Health Inc. (AWHL) since January 1, 2025. The newest filing on record that lists Jeffrey Cohen as Board Member at Aspira Women's Health Inc. (AWHL) is dated April 11, 2025. Jeffrey Cohen has spoken on 4 earnings calls across 3 companies, most recently for Vericel Corp on July 30, 2026. Those appearances were for Nano-X Imaging Ltd. (NNOX), Vericel Corp (VCEL) and Fractyl Health, Inc. (GUTS). Aspira Women's Health Inc. is classified in the Diagnostics & Research industry within the Healthcare sector. Other companies whose calls Jeffrey Cohen spoke on are classified in the Healthcare sector. Other leadership on record at Aspira Women's Health Inc. includes John Fraser (CEO and Board Member), Michael Buhle (CEO), Nicole Sandford (CEO and CFO) and 7 others.
“So, Just a couple, I did want to follow up on sales organization and back half and potential expansion. Could you talk about back half? Do you plan to add commercial folks, at least domestically, and then maybe talk about what preparations are being made in the UK from a commercial standpoint prior to launch?”
“Firstly, could you talk about the Telerad business? And you did call out customer retention, increased rates, and increased volumes. Could you kind of drill into that a little bit for our benefit as far as rates go and number of customers and volumes and utilization?”
“And as a follow-up, could you maybe talk about any net material ads or changes to the IP portfolio in the past quarter, including both potentially Rejuva as well?”
“I'd like you to dive in a little further. So could you talk a little bit about your footprint and commercial organization, mainly related in the U.S. as far as teams that are direct sales organizations, and talk a little bit about how that works with your distribution channels in the U.S.?”
2025-01-01–present
Last confirmed April 11, 2025
Investor
Analyst
Source not stated
Ladenburg Thalmann & Company
Analyst
Source not stated
Diagnostics & Research · Healthcare
Board Member
2025-01-01–present
NNOX
Medical Devices · Healthcare
VCEL
Biotechnology · Healthcare
GUTS
Biotechnology · Healthcare